Cramer backs Eli Lilly despite rival's GLP-1 lawsuit

CNBC's Jim Cramer reaffirmed his support for Eli Lilly stock despite a GLP-1-related lawsuit filed by a rival company. Cramer discussed his reasoning during the CNBC Investing Club's weekday Morning Meeting. The GLP-1 drug sector, which includes blockbuster weight-loss treatments, continues to attract close investor scrutiny.